Dataset Information

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

ABSTRACT:

Background

Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated.

Methods

We focused on patients with a WHO-defined moderate COVID-19 requiring hospitalization in a medical ward. We collected plasma and serum from three independent cohorts (N = 626 patients) and measured calprotectin amount at admission. We performed longitudinal measures of calprotectin in 457 of these patients (1461 samples) and used a joint latent class mixture model in which classes were defined by age, body mass index and comorbidities to identify calprotectin trajectories predicting the risk of transfer into an intensive care unit or death.

Findings

After adjustment for age, sex, body mass index and comorbidities, the predictive value of baseline calprotectin in patients with moderate COVID19 could be refined by serial monitoring of the biomarker. We discriminated three calprotectin trajectories associated with low, moderate, and high risk of poor outcome, and we designed an algorithm available as online software (https://calpla.gustaveroussy.fr:8443/) to monitor the probability of a poor outcome in individual patients with moderate COVID-19.

Interpretation

These results emphasize the clinical interest of serial monitoring of calprotectin amount in the peripheral blood to anticipate the risk of poor outcomes in patients with moderate COVID-19 hospitalized in a standard care unit.

Funding

The study received support (research grants) from ThermoFisher immunodiagnostics (France) and Gustave Roussy Foundation.

SUBMITTER: Chapuis N

PROVIDER: S-EPMC9132728 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

Chapuis Nicolas N Ibrahimi Nusaibah N Belmondo Thibaut T Goulvestre Claire C Berger Anne-Emmanuelle AE Mariaggi Alice-Andrée AA Andrieu Muriel M Chenevier-Gobeaux Camille C Bayle Arnaud A Campos Lydia L Cheurfa Cherifa C Chocron Richard R Diehl Jean-Luc JL Doumenc Benoît B Duchemin Jérôme J Duprat Manon M François Fabien F Gendron Nicolas N Mirault Tristant T Pène Frédéric F Philippe Aurélien A Pommeret Fanny F Sanchez Olivier O Smadja David M DM Szwebel Tali-Anne TA Silvin Aymeric A Ginhoux Florent F Lacroix Ludovic L Jules-Clément Gérôme G Rapeteramana Sarobidy S Mavier Colette C Steller Laura L Perniconi Barbara B André Fabrice F Drubay Damien D Fontenay Michaela M Hüe Sophie S Paul Stéphane S Solary Eric E

EBioMedicine 20220526

<h4>Background</h4>Severe COVID-19 is associated with a high circulating level of calprotectin, the S100A8/S100A9 alarmin heterodimer. Baseline calprotectin amount measured in peripheral blood at diagnosis correlates with disease severity. The optimal use of this biomarker along COVID-19 course remains to be delineated.<h4>Methods</h4>We focused on patients with a WHO-defined moderate COVID-19 requiring hospitalization in a medical ward. We collected plasma and serum from three independent cohor ...[more]

PMID: 35644124

Similar Datasets

Project description:BackgroundCalprotectin is an inflammatory marker mainly released by activated neutrophils that is increased in acute severe COVID-19. After initial recovery, some patients have persistent respiratory impairment with reduced diffusion capacity of the lungs for carbon monoxide (DLCO) months after infection. Underlying causes of this persistent impairment are unclear. We aimed to investigate the correlation between circulating calprotectin, persistent lung functional impairment and intensive care unit (ICU) stay after COVID-19 in two university hospital centres in Switzerland.MethodsCalprotectin levels were measured in serum from 124 patients (50% male) from the Bern cohort (post-ICU and non-ICU patients) and 68 (76% male) from the Lausanne cohort (only post-ICU patients) four months after COVID-19. Calprotectin was correlated with clinical parameters. Multivariate linear regression (MLR) was performed to evaluate the independent association of calprotectin in different models.ResultsOverall, we found that post-ICU patients, compared to non-ICU, were significantly older (age 59.4 ± 13.6 (Bern), 60.5 ± 12.0 (Lausanne) vs. 48.8 ± 13.4 years) and more obese (BMI 28.6 ± 4.5 and 29.1 ± 5.3 vs. 25.2 ± 6.0 kg/m2, respectively). 48% of patients from Lausanne and 44% of the post-ICU Bern cohort had arterial hypertension as a pre-existing comorbidity vs. only 10% in non-ICU patients. Four months after COVID-19 infection, DLCO was lower in post-ICU patients (75.96 ± 19.05% predicted Bern, 71.11 ± 18.50% Lausanne) compared to non-ICU (97.79 ± 21.70% predicted, p < 0.01). The post-ICU cohort in Lausanne had similar calprotectin levels when compared to the cohort in Bern (Bern 2.74 ± 1.15 µg/ml, Lausanne 2.49 ± 1.13 µg/ml vs. non-ICU 1.86 ± 1.02 µg/ml; p-value < 0.01). Calprotectin correlated negatively with DLCO (r= -0.290, p < 0.001) and the forced vital capacity (FVC) (r= -0.311, p < 0.001).ConclusionsSerum calprotectin is elevated in post-ICU patients in two independent cohorts and higher compared to non-ICU patients four months after COVID-19. In addition, there is a negative correlation between calprotectin levels and DLCO or FVC. The relationship between inflammation and lung functional impairment needs further investigations.Trial registrationNCT04581135.

Dataset Information

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

Background

Methods

Findings

Interpretation

Funding

Publications

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets